Sangamo BioSciences Inc. (SGMO) was one of the Russell 2000's biggest losers for Wednesday January 06 as the stock slid 8.87% to $8.12, a loss of $-0.79 per share. Starting at an opening price of $8.75 a share, the stock traded between $8.09 and $8.80 over the course of the trading day. Volume was 658,279 shares over 4,640 trades, against an average daily volume of 1.3 million shares and a total float of 70.05 million.
The losses send Sangamo BioSciences Inc. down to a market cap of $568.78 million. In the last year, Sangamo BioSciences Inc. has traded between $19.25 and $5.30, and its 50-day SMA is currently $8.29 and 200-day SMA is $9.81.
Sangamo BioSciences Inc is a clinical stage biopharmaceutical company. The Company is engaged in the research, development & commercialization of engineered DNA-binding proteins for the development of novel therapeutic strategies for unmet medical needs.
Sangamo BioSciences Inc. is based out of Richmond, CA and has some 102 employees. Its CEO is Edward O. Lanphier.
For a complete fundamental analysis analysis of Sangamo BioSciences Inc., check out Equities.com’s Stock Valuation Analysis report for SGMO. To see the latest independent stock recommendations from Equities.com’s analysts, visit our Research section.
The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It's maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.
Russell's indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It's a simple approach that gives a broad, unbiased look at the small-cap market as a whole.
For more news on the financial markets, go to Equities.com. Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.
All data provided by QuoteMedia and was accurate as of 4:30PM ET.